<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: The present study sought to ascertain the prevalence of impaired awareness of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> (IAH) in people with insulin-treated Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (T2DM) and its effect on risk of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Data were obtained from 122 people with insulin-treated T2DM (63 male; mean (SD) HbA1c 8.4% (1.5); median (inter quartile range, IQR) age, 67 (58-72) years; duration of T2DM 15 (10-20) years; duration of insulin therapy, 6 (4-9) years) </plain></SENT>
<SENT sid="2" pm="."><plain>A questionnaire was used to evaluate <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> awareness status and estimate the frequency of severe <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> (SH) in the preceding year </plain></SENT>
<SENT sid="3" pm="."><plain>Capillary blood <z:chebi fb="105" ids="17234">glucose</z:chebi> was monitored prospectively over a 4-week period to document biochemical <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The prevalence of IAH was 9.8% </plain></SENT>
<SENT sid="5" pm="."><plain>In the subgroup with IAH the incidence of SH in the preceding year was 17-fold higher than those with <z:mpath ids='MPATH_458'>normal</z:mpath> <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> awareness (0.83 (1.12) vs. 0.05 (0.28) episodes per patient; p&lt;0.001 (n=122)) and had a five-fold higher incidence of biochemical <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> (2.43 (4.39) vs. 0.46 (1.21) episodes; p&lt;0.001 (n=63)) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: The prevalence of IAH in insulin-treated T2DM was associated with higher frequencies of SH and biochemical <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Therefore the presence of IAH in those with insulin-treated T2DM should be evaluated at clinical review </plain></SENT>
</text></document>